Sarfez Pharmaceuticals, Inc.

2 trials changed in the last 30 days: 1 stopped, 1 with a notable change, 0 with minor changes only.

1. Stopped

   NEPHRON · Benefit of Finerenone Versus a Fixed Dose Combination…NEPHRON · Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone · Hypertension and Chronic Kidney Disease

   Trial status changed: Recruiting → Withdrawn

   Also in this update: Primary completion date changed from estimate of Jul 2026 to Sep 17, 2026

   Sarfez Pharmaceuticals, Inc.·Phase 3· NCT07223502· Registry history of NCT07223502 on ClinicalTrials.gov (opens the registry)

   Sep 22, 2026

2. Notable

   NEXT-HF · Natriuretic Effects of ER Torsemide to IR Torsemide…NEXT-HF · Natriuretic Effects of ER Torsemide to IR Torsemide · Heart Failure

   Reclassified as withdrawn (was completed)

   Sarfez Pharmaceuticals, Inc.·Phase 4· NCT06995144· Registry history of NCT06995144 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.